SCHEMBL7000102

SCHEMBL7000102

O=C(O)c1[c]cc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 3/20 0.46
CES2 O00748 3/20 0.42
CES1 P23141 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
P2RX1 P51575 1/20 0.39
EPHX2 P34913 2/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
PTPN1 P18031 2/20 0.37
NR4A1 P22736 1/20 0.37
NR4A2 P43354 1/20 0.37
NR4A3 Q92570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133046 0.82 KMT2A (0.44) SRD5A2CES2CES1KDM4EALDH1A1
SCHEMBL5759258 0.78 ALDH1A1 (0.44) CES2CES1KDM4EALDH1A1NPC1
SCHEMBL17046292 0.78 CFTR (0.47) CES2CES1KDM4EALDH1A1NPC1
SCHEMBL27459481 0.72 GABRP (0.34) CES2CES1KDM4EALDH1A1HPGD
SCHEMBL4628369 0.71 KDM4E (0.44) SRD5A2CES2CES1KDM4EALDH1A1
SCHEMBL2780243 0.70 TSHR (0.50) SRD5A2CES2CES1KDM4EALDH1A1
SCHEMBL21268187 0.70 KIF11 (0.43) CES2CES1KDM4EALDH1A1NPC1
SCHEMBL9023985 0.68 PTGDR2 (0.47) PTPN1
SCHEMBL4030667 0.68 TPMT (0.44) KDM4ERXRARXRBPTPN1GSK3B
SCHEMBL4957915 0.68 TSHR (0.48) SRD5A2CES2CES1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153713-A1 HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2022-05-19 US claimed
US-20220153688-A1 HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2022-05-19 US claimed
EP-3992184-A1 HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) 2022-05-04 EP claimed
EP-3992185-A1 HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) 2022-05-04 EP claimed
CN-113105411-A Hydrazone amide derivatives and pharmaceutical compositions 深圳市三启药物开发有限公司 2021-07-13 CN claimed
EP-1270000-A2 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis Pfizer Products Inc. (US) 2003-01-02 EP claimed
EP-0963755-A2 Use of benzopyranes for preventing allograft rejection Pfizer Products Inc. (US) 1999-12-15 EP claimed
EP-0943339-A2 Method of preventing allograft rejection Pfizer Products Inc. (US) 1999-09-22 EP claimed
US-5948813-A Method of preventing allograft rejection PFIZER INC. (US) 1999-09-07 US claimed
EP-0836850-A2 Method of preventing allograft rejection PFIZER INC. (US) 1998-04-22 EP claimed
US-5684046-A LEUKOTRIENE B4 ANTAGONIST AS ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS PFIZER INC (US) 1997-11-04 US claimed
EP-0623123-B1 Benzopyran and related LTB4-antagonists PFIZER (US) 1997-04-23 EP claimed
US-5552435-A ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS PFIZER INC. (US) 1996-09-03 US claimed
CN-113105411-B Hydrazone amide derivatives and pharmaceutical compositions 深圳市三启药物开发有限公司 2023-03-17 CN disclosed
US-20220153713-A1 HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2022-05-19 US disclosed
US-20220153688-A1 HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2022-05-19 US disclosed
EP-0623123-B1 Benzopyran and related LTB4-antagonists PFIZER (US) 1997-04-23 EP disclosed
US-5552435-A ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS PFIZER INC. (US) 1996-09-03 US disclosed
EP-0623123-A1 BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. PFIZER (US) 1994-11-09 EP disclosed
WO-1993015067-A1 BENZOPYRAN AND RELATED LTB4 ANTAGONISTS PFIZER INC. (US) 1993-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153688-A1 HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS SOST, HDAC5, PTH1R SRD5A2 329/4885CES2 3880/4885CES1 1088/4885
US-20220153713-A1 HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA FH, HDGF, HRH4 SRD5A2 130/4885CES2 4632/4885CES1 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.